About this Journal Submit a Manuscript Table of Contents
ISRN Pharmacology
Volume 2012 (2012), Article ID 527679, 4 pages
http://dx.doi.org/10.5402/2012/527679
Research Article

Bioequivalence Study of Donepezil Hydrochloride Tablets in Healthy Male Volunteers

Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

Received 15 September 2012; Accepted 3 October 2012

Academic Editors: F. J. Miranda and T. B. Vree

Copyright © 2012 Noppamas Rojanasthien et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. W. Sifton, Ed., Phyaician's Deak Reference, Medical Economics, Montvale, NJ, USA, 2000.
  2. S. Jackson, R. J. Ham, and D. Wilkinson, “The safety and tolerability of donepezil in patients with Alzheimer's disease,” British Journal of Clinical Pharmacology, vol. 58, supplement 1, pp. 1–8, 2004. View at Scopus
  3. D. Standaert and A. Young, “Treatment of central nervous system degenerative disorder,” in Goodman & Gilman's the Pharmacological Basis of Therapeutics, L. L. Brunton, Ed., pp. 538–540, McGraw-Hill, New York, NY, USA, 11th edition, 2006.
  4. S. L. Rogers and L. T. Friedhoff, “Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study,” European Neuropsychopharmacology, vol. 8, no. 1, pp. 67–75, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. P. J. Tiseo, K. Foley, and L. T. Friedhoff, “An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired venal function,” British Journal of Clinical Pharmacology, Supplement, vol. 46, supplement 1, pp. 56–60, 1998. View at Scopus
  6. X. Y. Hao, L. Ding, L. M. Li, X. J. Bian, and S. Q. Zhang, “Bioequivalence of donepezil capsule and tablet in human,” Yaoxue Xuebao, vol. 38, no. 5, pp. 392–394, 2003. View at Scopus
  7. Y. Lu, H. Wen, W. Li, Y. Chi, and Z. Zhang, “Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects,” Journal of Chromatographic Science, vol. 42, no. 5, pp. 234–237, 2004. View at Scopus
  8. S. L. Rogers and L. T. Friedhoff, “Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses,” British Journal of Clinical Pharmacology, vol. 46, supplement 1, pp. 1–6, 1998. View at Scopus
  9. A. Ohnishi, M. Mihara, H. Kamakura et al., “Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects,” Journal of Clinical Pharmacology, vol. 33, no. 11, pp. 1086–1091, 1993. View at Scopus
  10. M. Mihara, A. Ohnishi, Y. Tomono et al., “Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers,” International Journal of Clinical Pharmacology Therapy and Toxicology, vol. 31, no. 5, pp. 223–229, 1993. View at Scopus
  11. R. L. Nation and L. N. Sansom, “Bioequivalence requirements for generic products,” Pharmacology and Therapeutics, vol. 62, no. 1-2, pp. 42–55, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Sauter, V. W. Steinijans, E. Diletti, A. Bohm, and H. U. Schulz, “Presentation of results from bioequivalence studies,” International Journal of Clinical Pharmacology Therapy and Toxicology, vol. 30, supplement 1, pp. 233–256, 1992. View at Scopus
  13. Criteria and Guideline For the Bioequivalence Study of Generic Drugs, Thai Food and Drug Administration, 2000.